Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Daiichi Sankyo
Queensland Health
Healthtrust
McKinsey
Express Scripts
Fuji
Cantor Fitzgerald
Merck

Generated: September 25, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,338,478

« Back to Dashboard

Which drugs does patent 8,338,478 protect, and when does it expire?

Patent 8,338,478 protects TOVIAZ and is included in one NDA.

This patent has fifty-three patent family members in twenty-eight countries.

Summary for Patent: 8,338,478
Title:Derivatives of 3,3-diphenylpropylamines
Abstract: The invention concerns novel derivatives of 3,3-diphenyl-propylamines, methods for their preparation, pharmaceutical compositions containing the novel compounds, and the use of the compounds for preparing drugs. More particularly, the invention relates to novel prodrugs of antimuscarinic agents with superior pharmacokinetic properties compared to existing drugs such as oxybutynin and tolterodine, methods for their preparation, pharmaceutical compositions containing them, a method of using said compounds and compositions for the treatment of urinary incontinence, gastrointestinal hyperactivity (irritable bowel syndrome) and other smooth muscle contractile conditions.
Inventor(s): Meese; Claus (Monheim, DE), Sparf; Bengt (Trangsund, DE)
Assignee: UCB Pharma GmbH (Monheim, DE)
Application Number:13/161,049
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,338,478
Patent Claim Types:
see list of patent claims
Compound; Use; Composition;

Drugs Protected by US Patent 8,338,478

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Pfizer TOVIAZ fesoterodine fumarate TABLET, EXTENDED RELEASE;ORAL 022030-001 Oct 31, 2008 AB RX Yes No ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF OVERACTIVE BLADDER WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND FREQUENCY ➤ Sign Up
Pfizer TOVIAZ fesoterodine fumarate TABLET, EXTENDED RELEASE;ORAL 022030-002 Oct 31, 2008 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF OVERACTIVE BLADDER WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND FREQUENCY ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,338,478

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
98108608May 12, 1998

International Family Members for US Patent 8,338,478

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 220056 ➤ Sign Up
Australia 4141299 ➤ Sign Up
Australia 748057 ➤ Sign Up
Brazil 9910406 ➤ Sign Up
Canada 2328920 ➤ Sign Up
China 100491336 ➤ Sign Up
China 1207268 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
UBS
Colorcon
Mallinckrodt
US Department of Justice
Federal Trade Commission
Fish and Richardson
Baxter
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.